Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
HH Sum-XXII Holdings Limited
Cayman Islands
- Ownership
- Private
- Development stage
- Other
01
Overview
HH Sum-XXII Holdings Limited participated as part of a buyer consortium in a proposed going-private transaction for China Biologic Products Holdings, Inc. in 2019-2020, acquiring 210,876 ordinary shares at US$120.00 per share from Double Double Holdings Limited. It is affiliated with Hillhouse Capital and involved in biologics/healthcare investments.
- Industry
- Investors
02
Partnerships
Beachhead Holdings LimitedPW Medtech Group LimitedCITIC Capital China Partners IV, L.P.V-Sciences Investments Pte. Ltd.Double Double Holdings Limited
Beyond the preview
Go deeper on HH Sum-XXII Holdings Limited.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HH Sum-XXII Holdings Limited.